You are about to leave an AbbVie Canada site, a Web site maintained by AbbVie Corporation.

This link is provided for your convenience only. AbbVie Corporation takes no responsibility for the content of any Web site maintained by any third party and makes no representation as to the accuracy or completeness of any information contained on this or any subsequent link.

Do you wish to leave this site?

Yes No

You are here

Complete-PsA

Canadian HUMIRA Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis

    Status Recruiting
    Related Conditions
    Psoriatic Arthritis

Enrollment Details

Phases: 

  • I
  • II
  • III
  • IV
Study Type:  Observational

This is a type IV phase trial.

Protocol ID
P12-666

Brief summary

Top

The current study will assess the real-life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).

Participant Attributes :
  • Male and Female
  • Ages 18 Years to 99 Years

Canada: 27

0
Barrie, ON
1
Ottawa, ON
2
Burlington, ON
3
Cranbrook, BC
4
Halifax, NS
5
Hamilton, ON
6
Hamilton, ON
7
Kamloops, BC
8
Markham, ON
9
Milton, ON
10
Mississauga, ON
11
Montreal, QC
12
Montreal, QC
13
Ottawa, ON
14
Montreal, QC
15
Owen Sound, ON
16
Penticton, BC
17
Quebec, QC
18
Rimouski, QC
19
St. John's, NL
20
Sydney, NS
21
Toronto, ON
22
Toronto, ON
23
Trois-Rivières, QC
24
Vancouver, BC
25
Victoria, BC
26
Winnipeg, MB
Would you like to know more about this trial?

Study Design

  • The general design that describes the strategy for identifying and following up with participants during observational studies.
    ?

    Observational Model

    Cohort

  • The relationship between the observation period and the time of patient enrollment. Time perspective can be prospective: looking forward using periodic observations usually collected following patient enrollment, or retrospective: looking back using observations usually collected prior to patient selection and enrollment.
    ?

    Time Perspective

    Prospective

    • Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel
    • Active Psoriatic Arthritis (PsA) with three (3) or more tender and swollen joints as well as active psoriatic skin lesions or confirmed history of psoriasis
    • Inadequate response or non-tolerant to current disease-modifying antirheumatic drugs (DMARD) based treatment for PsA
    • Currently participating in another prospective study including controlled clinical trials and observational studies
    • Patient cannot or will not sign informed consent
    • Stable disease with adequate tolerance and response to current treatment and no change in treatment is indicated
    • Previous treatment with anti-tumor necrosis factor (anti-TNF)

More on this trial

Clinical Trials.gov